Early T-cell precursor acute lymphoblastic leukemia: report of 1 case and review of literature
10.3760/cma.j.cn115356-20210823-00188
- VernacularTitle:急性早期前体T淋巴母细胞白血病1例并文献复习
- Author:
Haoyun JIANG
1
;
Qiqi JIN
;
Ye HAN
;
Ying SONG
;
Yin WANG
;
Ye CHAI
;
Pengyun ZENG
;
Lingling YUE
;
Chongyang WU
Author Information
1. 兰州大学第二医院血液科，兰州 730030
- Keywords:
Precursor T-cell lymphoblastic leukemia-lymphoma;
Early T-cell precursor acute lymphoblastic leukemia;
Peripheral T-cell lymphoma-not otherwise specifie
- From:
Journal of Leukemia & Lymphoma
2022;31(7):423-426
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To improve the understanding of the diagnosis and treatment of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL).Methods:The clinical data of a patient with ETP-ALL who was misdiagnosed as peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) admitted to the Second Hospital of Lanzhou University in October 2020 were retrospectively analyzed, and the relevant literature was reviewed.Results:The patient who presented "inguinal lymphadenopathy" as the first symptom underwent lymph node biopsy and pathological examination at local hospital, and he was diagnosed as PTCL-NOS according to the consultation of another 2 hospitals. After 2 courses of chemotherapy (CHOPE regimen, GLD regimen, unknown specific medication and dosage), the therapeutic efficacy was poor. For further diagnosis and treatment, this patient came to Lanzhou University Second Hospital. Flow cytometry found blast cells in the bone marrow, and then other related examinations were completed, he was finally diagnosed as ETP-ALL. The chemotherapy regimens of Hyper-CVAD and EA were alternatively used, progressive disease (PD) occurred after 3 courses of treatment, and chidamide was added in the 4th and 5th courses of treatment, the disease still progressed, and the patient died after follow-up. The disease course of the patient was about 12 months.Conclusions:ETP-ALL has unique immunophenotypic characteristics. ETP-ALL patients have a low remission rate after conventional induction therapy, high recurrence rate and poor prognosis. Currently, there is no effective standard treatment regimen, and allogeneic hematopoietic stem cell transplantation or timely addition of new drugs may improve the prognosis.
